CFTR testing kit with streamlined workflow delivers reliable results in less than five hours
Learn MoreThe AmplideX® PCR/CE SMN1/2 Plus Kit is a clinical research tool providing the most comprehensive analysis of SMN1 and SMN2 currently available from a commercial kit.
Learn moreThe AmplideX® PCR/CE HTT Kit is a simple, robust, and reliable test for the detection of CAG trinucleotide repeats within the HTT gene, aberrations which are associated with the development of Huntington’s Disease (HD).
Read moreAsuragen, Inc has developed an Armored RNA Quant® SARS-CoV-2 Control for use in developing assays in response to the COVID-19 pandemic.
Learn more about our custom control offerings
Fragile X syndrome is a genetic disorder that is caused by a gene mutation on the X chromosome. Symptoms frequently include developmental delays, intellectual disabilities, and behavioral issues. Carriers for Fragile X don’t have Fragile X syndrome; however, they do have an increased chance of certain medical issues. Testing for Fragile X syndrome is important, especially for women who are pregnant or plan to become pregnant. Learn more about Fragile X from Ilana Garber, who shares her and her son Yaron’s journey with Fragile X syndrome as well as from Dr. Tamar Goldwaser, an OBGYN and medical geneticist.
Cystic fibrosis testing can be challenging for laboratories. Even though screening is recommended for all ethnicities, it can be difficult to provide reliable results for everyone, since most CFTR assays were designed based on outdated, ethnically-homogeneous data. Additionally, some assay workflows can be time-consuming, cost-prohibitive, or cumbersome for labs to use. In this event, Asuragen is pleased to unveil the AmplideX® PCR/CE CFTR Kit*, which is designed to provide the broadest coverage** of the U.S. population of any available targeted kit, with an easy-to-implement workflow. Recent large-scale diverse datasets informed assay design to bridge coverage gaps left by other targeted assays, while the application of AmplideX technology streamlines the testing process. Register now for access to: Live webinars with C.E. credits and Q&A sessions Presentations from knowledge experts in CFTR gene coverage variants Detailed AmplideX PCR/CE CFTR Kit information How to expand your lab menu with the AmplideX portfolio The opportunity to chat with an AmplideX expert For more information on the AmplideX PCR/CE CFTR Kit*, visit Asuragen.com/CFTR. Practical CFTR Testing To Address Coverage Gaps with the AmplideX® PCR/CE CFTR Kit* John N. Milligan, PhD Senior Manager, Research & Development, Asuragen Learn how recent large-scale diverse population studies provide a greater understanding of the diversity of CFTR variants and how this data has informed the AmplideX PCR/CE CFTR Kit* design to provide the broadest coverage** of any targeted CFTR testing kit. ________________________________________ Comprehensive Yet Streamlined Genetic Testing with AmplideX® Technology Ninad Pendsé, MBA Senior Product Manager, Asuragen This webinar will present the relevant genetic information needed in three common carrier screening genes (CFTR, SMN1/2, and FMR1), as well as how AmplideX assays provides this information with simple, complementary workflows made for real-world use. _______________________________________ How Did They Do It? Real-World Lab Journeys to Genetic Test Implementation Andrew Kincaid – Senior Manager, Field Applications, Asuragen Tessa Gowan – Field Application Scientist, Asuragen Stephanie Borel, MS – Field Application Scientist, Asuragen Vivian Le – Field Application Scientist, Asuragen What does the process look like to implement a genetic assay in a molecular lab? What challenges need to be overcome and what support does Asuragen provide? This webinar will answer all those questions as our field application scientists present diverse real-world journeys of labs implementing AmplideX® genetic assays. ________________________________________ *For Research Use Only. Not for use in diagnostic procedures. **Based on Beauchamp KA, et al. Genet Med. 2019.
